Key regions: United Kingdom, Germany, France, South Korea, Italy
The COVID-19 pandemic has affected every country in the world, including Niger. As the world races to develop and distribute vaccines to combat the virus, the COVID-19 vaccines market in Niger has seen some notable trends and developments.
Customer preferences: Niger, like many other developing countries, has a low vaccination rate. The population is largely hesitant to receive vaccines due to mistrust and misinformation. Additionally, there is a preference for traditional medicine over Western medicine. This presents a challenge for the COVID-19 vaccines market in Niger as it tries to gain traction.
Trends in the market: Despite the challenges, the COVID-19 vaccines market in Niger is slowly gaining momentum. The government has launched a vaccination campaign to encourage the population to get vaccinated. This campaign has led to an increase in demand for vaccines, which has been met with supply from various sources such as the COVAX facility.
Local special circumstances: Niger is a landlocked country in West Africa with a population of over 24 million people. The country is one of the poorest in the world and faces a number of challenges such as food insecurity, poverty, and a lack of infrastructure. These challenges have made it difficult for the government to distribute vaccines to the population.
Underlying macroeconomic factors: The COVID-19 pandemic has had a significant impact on the economy of Niger. The country has experienced a decline in economic activity due to the pandemic and the measures taken to contain it. The government has had to redirect resources to combat the pandemic, which has further strained the economy. However, the country has received support from international organizations such as the World Bank and the International Monetary Fund to help mitigate the economic impact of the pandemic.In conclusion, the COVID-19 vaccines market in Niger is slowly gaining momentum despite the challenges posed by low vaccination rates and a preference for traditional medicine. The government's vaccination campaign and the supply of vaccines from various sources have helped to increase demand for vaccines. However, the country's economic challenges and lack of infrastructure remain a hindrance to the distribution of vaccines to the population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
